Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | SAT1 | P21673 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16789969 | 0.93 | CYP2C19 (0.52) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL20003253 | 0.91 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL40907 | 0.84 | — | — | |
| SCHEMBL26705092 | 0.83 | TSHR (0.52) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL14222478 | 0.83 | TSHR (0.59) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL23793168 | 0.81 | CYP2C19 (0.46) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL19966296 | 0.81 | TDP1 (0.40) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL27462008 | 0.81 | CYP2C19 (0.46) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL18331653 | 0.81 | KDM5A (0.38) | TDP1KDM5AKDM4CPAOXALDH1A1 | |
| SCHEMBL14985825 | 0.80 | CYP2C19 (0.43) | CYP2C19MEN1GLAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076116-A1 | SELECTIVE BLOCKING OF METAL SURFACES USING BIFUNCTIONAL SELF-ASSEMBLED MONOLAYERS | APPLIED MATERIALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2928581-B1 | PROCESS FOR ABSORPTION OF CO2 FROM A GAS MIXTURE USING AN AQUEOUS SOLUTION OF A DIAMINE | EVONIK DEGUSSA GMBH (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20150321139-A1 | PROCESS FOR ABSORPTION OF CO2 FROM A GAS MIXTURE USING AN AQUEOUS SOLUTION OF A DIAMINE | EVONIK INDUSTRIES AG (DE) | 2015-11-12 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016307-A1 | NOVEL COMPOUNDS | MET, HGF, HGFAC | CYP2C19 1127/4885MEN1 383/4885GLA 3262/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CYP2C19 2590/4885MEN1 3926/4885GLA 1522/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CYP2C19 2590/4885MEN1 3926/4885GLA 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.